SRC - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	BARD1	BRCA1 associated RING domain 1	HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) UCH proteinases Metalloprotease DUBs Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Defective DNA double strand break response due to BRCA1 loss of function Defective DNA double strand break response due to BARD1 loss of function
Novel	CUL4B	cullin 4B	Recognition of DNA damage by PCNA-containing replication complex DNA Damage Recognition in GG-NER Formation of Incision Complex in GG-NER Dual Incision in GG-NER Formation of TC-NER Pre-Incision Complex Transcription-Coupled Nucleotide Excision Repair (TC-NER) Dual incision in TC-NER Gap-filling DNA repair synthesis and ligation in TC-NER Neddylation		Syndromic X-linked mental retardation, including: Turner type (MRXST); Siderius type (MRXSSD) ; Cabezas type (MRXC); Raymond type (MRXSR); Type10 (MRXS10); Type14 (MRXS14); Mental retardation with isolated growth hormone deficiency (MRGH)
Novel	PI3	peptidase inhibitor 3	Antimicrobial peptides Formation of the cornified envelope
Novel	DPYD	dihydropyrimidine dehydrogenase	Pyrimidine catabolism	(5S)-5-Iododihydro-2,4(1H,3H)-pyrimidinedione NADPH 6-Carboxymethyluracil Flavin adenine dinucleotide Flavin mononucleotide Uracil Eniluracil 5-Iodouracil Gimeracil Tegafur-uracil	Dihydropyrimidine dehydrogenase deficiency
Novel	ENPP7	ectonucleotide pyrophosphatase/phosphodiesterase 7	Glycosphingolipid metabolism
Novel	FMR1	FMRP translational regulator 1			Premature ovarian failure Fragile X Syndrome, including: Fragile X Syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)
Novel	PLTP	phospholipid transfer protein
Novel	PTPRT	protein tyrosine phosphatase receptor type T
Novel	ZNF687	zinc finger protein 687
	HRAS	HRas proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants	Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Bladder cancer Penile cancer Squamous cell carcinoma Thyroid cancer Cervical cancer Hepatocellular carcinoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
	PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Extra-nuclear estrogen signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Isoprenaline SF1126 Enzastaurin Wortmannin
	HSP90AA1	heat shock protein 90 alpha family class A member 1	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation vRNP Assembly Regulation of actin dynamics for phagocytic cup formation eNOS activation Regulation of PLK1 Activity at G2/M Transition Scavenging by Class F Receptors Scavenging by Class F Receptors HSP90 chaperone cycle for steroid hormone receptors (SHR) HSF1 activation Attenuation phase HSF1-dependent transactivation Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Sema3A PAK dependent Axon repulsion VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated vascular permeability Uptake and function of diphtheria toxin PIWI-interacting RNA (piRNA) biogenesis Anchoring of the basal body to the plasma membrane Constitutive Signaling by EGFRvIII Regulation of necroptotic cell death Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Downregulation of ERBB2 signaling ESR-mediated signaling Extra-nuclear estrogen signaling RHOBTB2 GTPase cycle Estrogen-dependent gene expression Chaperone Mediated Autophagy Constitutive Signaling by Overexpressed ERBB2 Aggrephagy Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Potential therapeutics for SARS	Rifabutin Nedocromil 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine Geldanamycin 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine Quercetin 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE Tanespimycin SNX-5422 N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol CCT-018159 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE Copper Polaprezinc Alvespimycin
	MAPK3	mitogen-activated protein kinase 3	MAPK3 (ERK1) activation RAF-independent MAPK1/3 activation ISG15 antiviral mechanism Spry regulation of FGF signaling Frs2-mediated activation ERK/MAPK targets ERK/MAPK targets ERKs are inactivated Regulation of actin dynamics for phagocytic cup formation Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Oncogene Induced Senescence FCERI mediated MAPK activation Regulation of HSF1-mediated heat shock response NCAM signaling for neurite out-growth RSK activation Signal transduction by L1 Activation of the AP-1 family of transcription factors Thrombin signalling through proteinase activated receptors (PARs) Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate NADPH Oxidases RAF/MAP kinase cascade MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RNA Polymerase I Promoter Opening Signal attenuation Advanced glycosylation endproduct receptor signaling Gastrin-CREB signalling pathway via PKC and MAPK ESR-mediated signaling RUNX2 regulates osteoblast differentiation Regulation of PTEN gene transcription Regulation of the apoptosome activity Estrogen-dependent nuclear events downstream of ESR-membrane signaling Suppression of apoptosis Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants FCGR3A-mediated phagocytosis Growth hormone receptor signaling	Sulindac Acetylsalicylic acid Minocycline Arsenic trioxide Purvalanol 5-iodotubercidin Seliciclib Cholecystokinin Ulixertinib
	PTPN11	protein tyrosine phosphatase non-receptor type 11	Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Costimulation by the CD28 family CTLA4 inhibitory signaling PD-1 signaling Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA signaling Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon FLT3 Signaling STAT5 Activation STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants	Dodecyltrimethylammonium	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Metachondromatosis
	LYN	LYN proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Fc epsilon receptor (FCERI) signaling Fc epsilon receptor (FCERI) signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization FCERI mediated NF-kB activation CD28 co-stimulation CTLA4 inhibitory signaling EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells Dectin-2 family CD209 (DC-SIGN) signaling CD22 mediated BCR regulation Cyclin D associated events in G1 Platelet Adhesion to exposed collagen Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Growth hormone receptor signaling Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Bosutinib Ponatinib Nintedanib Fostamatinib
	PRKACA	protein kinase cAMP-activated catalytic subunit alpha	PKA-mediated phosphorylation of CREB PKA-mediated phosphorylation of key metabolic factors Triglyceride catabolism PKA activation PKA activation in glucagon signalling DARPP-32 events Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling Regulation of insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins VEGFA-VEGFR2 Pathway CREB1 phosphorylation through the activation of Adenylate Cyclase CREB1 phosphorylation through the activation of Adenylate Cyclase Interleukin-3, Interleukin-5 and GM-CSF signaling Ion homeostasis Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'off' state Anchoring of the basal body to the plasma membrane CD209 (DC-SIGN) signaling MAPK6/MAPK4 signaling RET signaling AURKA Activation by TPX2 HDL assembly ROBO receptors bind AKAP5 Loss of phosphorylation of MECP2 at T308 Regulation of MECP2 expression and activity Regulation of glycolysis by fructose 2,6-bisphosphate metabolism ADORA2B mediated anti-inflammatory cytokines production ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis FCGR3A-mediated IL10 synthesis Factors involved in megakaryocyte development and platelet production	Pentanal Balanol Analog 2 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate Phosphonothreonine Balanol Analog 1 3,5-Diiodotyrosine Balanol Dexfosfoserine S,S-(2-Hydroxyethyl)Thiocysteine Hydroxyfasudil (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE H-89 5-(2-methylpiperazine-1-sulfonyl)isoquinoline N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE 3-pyridin-4-yl-1H-indazole 5-benzyl-1,3-thiazol-2-amine 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium Fasudil Myristic acid A-674563 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE Y-27632 Ellagic acid Fostamatinib
	TP53	tumor protein p53	Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Factors involved in megakaryocyte development and platelet production	Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Osteosarcoma Adrenal carcinoma Thyroid cancer Breast cancer Basal cell carcinoma Malignant melanoma Pancreatic cancer Gastric cancer Malignant pleural mesothelioma Non-small cell lung cancer Esophageal cancer Oral cancer Multiple myeloma Small cell lung cancer Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Glioma Squamous cell carcinoma Kaposi's sarcoma Cholangiocarcinoma Gallbladder cancer Cancer of the anal canal Hepatocellular carcinoma Choriocarcinoma Vulvar cancer Choroid plexus papilloma Burkitt lymphoma Adult T-cell leukemia Hairy-cell leukemia Bladder cancer Chronic lymphocytic leukemia (CLL) Penile cancer Endometrial Cancer Ovarian cancer Colorectal cancer Laryngeal cancer Chronic myeloid leukemia (CML)
	AKT1	AKT serine/threonine kinase 1	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling CTLA4 inhibitory signaling G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling	ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
	PLCG1	phospholipase C gamma 1	ISG15 antiviral mechanism Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PLCG1 events in ERBB2 signaling DAG and IP3 signaling PLC-gamma1 signalling Synthesis of IP3 and IP4 in the cytosol Downstream signal transduction Generation of second messenger molecules Role of phospholipids in phagocytosis Role of phospholipids in phagocytosis PECAM1 interactions EGFR interacts with phospholipase C-gamma DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Role of second messengers in netrin-1 signaling VEGFR2 mediated cell proliferation VEGFR2 mediated cell proliferation Constitutive Signaling by EGFRvIII Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 point mutants in cancer RET signaling Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Erythropoietin activates Phospholipase C gamma (PLCG) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through PLCG1 FCGR3A-mediated IL10 synthesis Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants
	CDK1	cyclin dependent kinase 1	MAPK3 (ERK1) activation E2F-enabled inhibition of pre-replication complex formation Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 Golgi Cisternae Pericentriolar Stack Reorganization Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes APC/C:Cdc20 mediated degradation of Cyclin B Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of the APC/C Phosphorylation of Emi1 Condensation of Prophase Chromosomes MASTL Facilitates Mitotic Progression Resolution of Sister Chromatid Cohesion Condensation of Prometaphase Chromosomes Regulation of PLK1 Activity at G2/M Transition Activation of NIMA Kinases NEK9, NEK6, NEK7 Initiation of Nuclear Envelope (NE) Reformation Nuclear Pore Complex (NPC) Disassembly Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Depolymerisation of the Nuclear Lamina Anchoring of the basal body to the plasma membrane MAPK6/MAPK4 signaling Ovarian tumor domain proteases TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Regulation of TP53 Degradation Mitotic Prophase G1/S-Specific Transcription Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition G2/M DNA replication checkpoint Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Transcriptional regulation by RUNX2	Indirubin-3'-monoxime Olomoucine Hymenialdisine SU9516 Alvocidib Alsterpaullone Seliciclib AT-7519 Fostamatinib

Search Results for: SRC